Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy

Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy

Abstract Background No study has comparing hepatitis B virus (HBV) relapse rates among patients with both cancer and hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) who completed anti-viral prophylaxis for chemotherapy and then stopped taking entecavir or tenofovir alafenamide (TAF)...

Full description

Bibliographic Details
Main Authors: Hsin-Wei Fang, Po-Lin Tseng, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Chien-Hung Chen
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Virology Journal
Subjects:
Entecavir
Tenofovir alafenamide
Rituximab
Chemotherapy
Chronic hepatitis B
Online Access:https://doi.org/10.1186/s12985-024-02338-6

Internet

https://doi.org/10.1186/s12985-024-02338-6

Similar Items